Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn-Strides has announced the approval of an abbreviated new drug application for flumazenil injection USP, 0.1mg/mL, packaged in 5mL and 10mL multiple dose vials, which is indicated for the complete or partial reversal of the sedative effects of benzodiazepines.
Subscribe to our email newsletter
Akorn-Strides, is a joint venture that was formed in 2005 by Akorn and Strides Arcolab.
Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said: “The joint venture has now placed purchase orders for five injectable abbreviated new drug application (ANDA) products, one for fosphenytoin sodium, two for ondansetron, one for flumazenil and one for an expected ANDA approval in the near term. The joint venture expects to launch these products in 2008.”